Mumbai-based healthtech disruptor Truemeds secured $85 million in new capital to accelerate its generic medication platform, prioritizing deep consumer affordability over the industry’s shift toward ultra-fast delivery. Co-founder Akshat Nayyar told TechCrunch that consumers often remain anchored to the premium pricing of prescribed brands, making the company’s mission to provide high-quality, low-cost alternatives a vital economic intervention for chronic patients.
Aggressive Discounting as a Market Differentiator
While the Indian e-pharmacy sector has largely pivoted toward “quick commerce” models, reducing average discounts from 25% to a standard 15%, Truemeds has moved in the opposite direction. The startup boosted its average discounts from 29% to 32% over the last year. For patients who transition from branded drugs to curated generics on the platform, total savings frequently reach 47%.
This pricing advantage stems from sophisticated procurement technology that grants manufacturers precise demand visibility. By enabling pharmaceutical companies to plan production cycles more efficiently for upcoming quarters, Truemeds secures better margins which it then passes directly to the end user. The company manages its own logistics in major hubs while utilizing cost-effective partners for broader distribution.
“Our four-hour delivery model meets the needs of chronic patients perfectly,” Nayyar stated. He emphasized that planned purchases allow for a more efficient supply chain, enabling the company to focus on maximizing user savings rather than maintaining the overhead required for sub-hour delivery speeds.
AI Integration and Diagnostic Expansion
Truemeds utilizes a proprietary algorithm to facilitate 10 to 12 million annual consultations, helping patients navigate the shift to generics. The system evaluates critical parameters including GMP certification of manufacturing plants and specific drug formulations—such as sugar-coating for pediatric use—to ensure alternative suggestions meet high clinical standards. The startup currently uses a chatbot for rapid query resolution but plans to deploy a more advanced AI system to personalize interactions based on historical user behavior.
The growth roadmap includes a significant expansion into the diagnostics sector. Through strategic partnerships with national pathology laboratories, Truemeds will pilot lab-testing services in several tier-2 cities within the next quarter. The objective is to replicate the generic drug success story in the testing market, positioning the startup as the lowest-cost provider for common diagnostic procedures.
To support this scale, Truemeds intends to increase its fulfillment center footprint by 300%, growing from 19 locations to nearly 60 within the next year. This expansion follows a previous $50 million funding round, of which the company still retains approximately 35% in liquid capital. The organization currently employs 2,800 professionals, with a core team of 250 based at its Mumbai headquarters and a growing engineering division in its new Bengaluru office.
